Sun Pharmaceutical Industries
BSE 524715
11 stories, newest first.
- Sun Pharma to present long-term UNLOXCYT data in advanced CSCC at ESMO 2026
- UNLOXCYT elevated to NCCN Category 2A option for locally advanced CSCC
- Sun Pharma to announce Q2 results on 30 October 2026; earnings call at 6:30 pm IST
- Board meeting on 30 October 2026 to consider Unaudited Q2/H1 FY27 results; trading window closed
- CRISIL and ICRA assign AAA to Sun Pharma's Rs.15000 crore proposed NCDs; AAA/A1+ facilities reaffirmed
- Board approves NCD issue up to INR 10,000 Crore; Independent Director resigns
- Board meeting on 12 October 2026 to consider NCD issuance of up to INR 15,000 Crore
- Announces $2.5 million endowed dermatology professorship at Mount Sinai
- LEQSELVI two-year data in severe alopecia areata shows sustained efficacy at EADV Congress 2026
- ESG Overview for FY 2025-26 submitted to exchanges
- Exclusive global licensing deal with LIB Therapeutics for PCSK9 inhibitor lerodalcibep, ex-US and China
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.